QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases

EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round Financing supports clinical activities for Company's two lead programs in ALS and pipeline development CAMBRIDGE, Mass., March 9, 2023 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Neurology, Venture Capital QurAlis , amyotrophic lateral sclerosis

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2047927

Source: HSMN NewsFeed - March 9, 2023 Category: Pharmaceuticals Source Type: news